Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29086789 | 0.87 | HTR2A (0.47) | HRH3PNMTASIC3PRMT5HTR2A | |
| SCHEMBL22858683 | 0.79 | HTR2C (0.51) | PNMTASIC3PRMT5HTR2AHTR2C | |
| SCHEMBL29608060 | 0.79 | HTR2C (0.51) | PNMTASIC3PRMT5HTR2AHTR2C | |
| SCHEMBL19684653 | 0.79 | HRH3 (0.38) | HRH3PNMTPRMT5TLR7RAD52 | |
| Hydrochloric Acid SCHEMBL23725869 | 0.78 | HTR2C (0.50) | PNMTASIC3PRMT5HTR2AHTR2C | |
| SCHEMBL19679215 | 0.76 | HTR2C (0.51) | PNMTASIC3PRMT5HTR2AHTR2C | |
| SCHEMBL19684924 | 0.73 | PARP10 (0.41) | KMT2A | |
| SCHEMBL17664979 | 0.71 | HTR2A (0.46) | HRH3TLR7HTR2AHTR2CHTR2B | |
| SCHEMBL19684577 | 0.71 | PNMT (0.50) | PNMTASIC3PRMT5HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL29216547 | 0.69 | PNMT (0.49) | PNMTASIC3PRMT5HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | HRH3 4115/4885PNMT 2003/4885ASIC3 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.